|
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about SU5416 and Paclitaxel in Treating Patients With Advanced Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. SU5416 and Paclitaxel in Treating Patients With Advanced Cancer Clinical research trials and SU5416 and Paclitaxel in Treating Patients With Advanced Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like SU5416 and Paclitaxel in Treating Patients With Advanced Cancer. SU5416 and Paclitaxel in Treating Patients With Advanced Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a SU5416 and Paclitaxel in Treating Patients With Advanced Cancer clinical trial. Subjects frequently get the best healthcare possible for their SU5416 and Paclitaxel in Treating Patients With Advanced Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SU5416 and Paclitaxel in Treating Patients With Advanced Cancer  SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
For Condition: unspecified adult solid tumor, protocol specific
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Beckman Research Institute
Synopsis: RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining SU5416 and paclitaxel in treating patients who have advanced cancer.
Details: OBJECTIVES: I. Determine the maximum tolerated dose of SU5416 when combined with paclitaxel in patients with advanced malignancies. II. Determine the toxicities and pharmacokinetics of this regimen in these patients. III. Determine the effects of this regimen on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays of endothelial cell proliferation, migration, and invasion. PROTOCOL OUTLINE: This is a dose escalation study of SU5416. Patients receive SU5416 IV over 1 hour twice weekly during the first week. During subsequent courses, SU5416 is administered on days 1, 4, 8, 11, 15, 18, 22, and 25. Paclitaxel begins on the second week of therapy and is administered IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. PROJECTED ACCRUAL: Approximately 24 patients will be accrued for this study within 12-18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically or cytologically proven advanced malignancy for which no satisfactory treatment exists - Must have tumor accessible by biopsy; Minimum of 1 baseline biopsy required - No brain metastases or primary CNS tumor --Prior/Concurrent Therapy-- - Biologic therapy: No prior SU5416 - Chemotherapy: No prior paclitaxel; Greater than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered - Endocrine therapy: Not specified - Radiotherapy: Greater than 4 weeks since prior radiotherapy and recovered - Surgery: See Disease Characteristics - Other: Recovered from any prior investigational agents; No other concurrent investigational agents --Patient Characteristics-- - Age: 18 and over - Performance status: WHO 0-2 - Life expectancy: At least 3 months - Hematopoietic: Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: SGOT and SGPT less than 2 times upper limit of normal unless due to presence of tumor; Bilirubin normal - Renal: Creatinine no greater than 1.5 mg/dL; Creatinine clearance greater than 60 mL/min - Cardiovascular: No uncompensated coronary artery disease by ECG or physical examination; No myocardial infarction or severe unstable/angina within the past 6 months; No severe peripheral vascular disease associated with diabetes mellitus; No severe deep vein or arterial thrombosis within the past 3 months - Pulmonary: No pulmonary embolism within the past 3 months - Other: Not pregnant or nursing; Negative pregnancy test Fertile patients must use effective contraception; No unstable or severe concurrent medical condition; No active uncontrolled infection; No history of allergic reaction to paclitaxel or Cremophor; No greater than grade 1 peripheral neuropathy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
PrzemyslawTwardowski, Study Chair, Beckman Research Institute
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
United States
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
United States
University of California Davis Cancer Center
Sacramento, California, 95817
United States
Additional Information:
Study ID Numbers: CDR0000068191; CHNMC-IRB-99098,CHNMC-PHI-30,NCI-T99-0086
Study Start Date: November 2000
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006257
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Gefitinib, Capecitabine, and Celecoxib in Treating Patients With Advanced Solid Tumors
2. Geldanamycin Analogue in Treating Patients With Advanced Cancer
3. Creatine in Treating Patients With Cancer-Associated Weight Loss
4. Combination Chemotherapy in Treating Patients With Solid Tumors
5. Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
|
|
|
|
|
|
|
|
